In a report released on September 21, Mark Massaro from BTIG reiterated a Buy rating on Castle Biosciences (CSTL – Research Report), with a price target of $47.00. The company’s shares closed yesterday at $25.00.
According to TipRanks, Massaro is an analyst with an average return of -3.3% and a 40.62% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Natera, Castle Biosciences, and Ginkgo Bioworks Holdings.
Castle Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $48.33, which is a 93.32% upside from current levels. In a report released on September 21, SVB Securities also maintained a Buy rating on the stock with a $50.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $76.02 and a one-year low of $15.58. Currently, Castle Biosciences has an average volume of 242.2K.
Based on the recent corporate insider activity of 54 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CSTL in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
